Your browser doesn't support javascript.
loading
Pharmacology of Antisense Drugs.
Bennett, C Frank; Baker, Brenda F; Pham, Nguyen; Swayze, Eric; Geary, Richard S.
Afiliação
  • Bennett CF; Ionis Pharmaceuticals, Carlsbad, California 92010; email: fbennett@isisph.com.
  • Baker BF; Ionis Pharmaceuticals, Carlsbad, California 92010; email: fbennett@isisph.com.
  • Pham N; Ionis Pharmaceuticals, Carlsbad, California 92010; email: fbennett@isisph.com.
  • Swayze E; Ionis Pharmaceuticals, Carlsbad, California 92010; email: fbennett@isisph.com.
  • Geary RS; Ionis Pharmaceuticals, Carlsbad, California 92010; email: fbennett@isisph.com.
Annu Rev Pharmacol Toxicol ; 57: 81-105, 2017 01 06.
Article em En | MEDLINE | ID: mdl-27732800
ABSTRACT
Recent studies have led to a greater appreciation of the diverse roles RNAs play in maintaining normal cellular function and how they contribute to disease pathology, broadening the number of potential therapeutic targets. Antisense oligonucleotides are the most direct means to target RNA in a selective manner and have become an established platform technology for drug discovery. There are multiple molecular mechanisms by which antisense oligonucleotides can be used to modulate RNAs in cells, including promoting the degradation of the targeted RNA or modulating RNA function without degradation. Antisense drugs utilizing various antisense mechanisms are demonstrating therapeutic potential for the treatment of a broad variety of diseases. This review focuses on some of the advances that have taken place in translating antisense technology from the bench to the clinic.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oligonucleotídeos Antissenso Limite: Animals / Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oligonucleotídeos Antissenso Limite: Animals / Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article